Logo image of NXTC

NEXTCURE INC (NXTC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NXTC - US65343E2072 - Common Stock

11.38 USD
+0.68 (+6.36%)
Last: 12/19/2025, 8:06:39 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NXTC. NXTC was compared to 530 industry peers in the Biotechnology industry. The financial health of NXTC is average, but there are quite some concerns on its profitability. NXTC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NXTC had negative earnings in the past year.
NXTC had a negative operating cash flow in the past year.
NXTC had negative earnings in each of the past 5 years.
In the past 5 years NXTC always reported negative operating cash flow.
NXTC Yearly Net Income VS EBIT VS OCF VS FCFNXTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

NXTC has a Return On Assets of -146.44%. This is amonst the worse of the industry: NXTC underperforms 85.34% of its industry peers.
With a Return On Equity value of -245.33%, NXTC is not doing good in the industry: 71.24% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -146.44%
ROE -245.33%
ROIC N/A
ROA(3y)-53.01%
ROA(5y)-39.92%
ROE(3y)-61.74%
ROE(5y)-45.48%
ROIC(3y)N/A
ROIC(5y)N/A
NXTC Yearly ROA, ROE, ROICNXTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NXTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NXTC Yearly Profit, Operating, Gross MarginsNXTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

More info and screens

5

2. Health

2.1 Basic Checks

NXTC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NXTC has more shares outstanding
There is no outstanding debt for NXTC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NXTC Yearly Shares OutstandingNXTC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
NXTC Yearly Total Debt VS Total AssetsNXTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

NXTC has an Altman-Z score of -18.24. This is a bad value and indicates that NXTC is not financially healthy and even has some risk of bankruptcy.
NXTC has a Altman-Z score of -18.24. This is amonst the worse of the industry: NXTC underperforms 82.89% of its industry peers.
NXTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.24
ROIC/WACCN/A
WACCN/A
NXTC Yearly LT Debt VS Equity VS FCFNXTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

NXTC has a Current Ratio of 2.97. This indicates that NXTC is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.97, NXTC is not doing good in the industry: 64.85% of the companies in the same industry are doing better.
A Quick Ratio of 2.97 indicates that NXTC has no problem at all paying its short term obligations.
NXTC's Quick ratio of 2.97 is on the low side compared to the rest of the industry. NXTC is outperformed by 62.41% of its industry peers.
Industry RankSector Rank
Current Ratio 2.97
Quick Ratio 2.97
NXTC Yearly Current Assets VS Current LiabilitesNXTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

NXTC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.87%.
EPS 1Y (TTM)3.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NXTC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.72% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.11%
EPS Next 2Y24.06%
EPS Next 3Y22.78%
EPS Next 5Y13.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NXTC Yearly Revenue VS EstimatesNXTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2028 2029 2030 10M 20M 30M 40M
NXTC Yearly EPS VS EstimatesNXTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NXTC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NXTC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NXTC Price Earnings VS Forward Price EarningsNXTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NXTC Per share dataNXTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as NXTC's earnings are expected to grow with 22.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.06%
EPS Next 3Y22.78%

More info and screens

0

5. Dividend

5.1 Amount

NXTC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

NEXTCURE INC

NASDAQ:NXTC (12/19/2025, 8:06:39 PM)

11.38

+0.68 (+6.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-04 2026-03-04/amc
Inst Owners32.85%
Inst Owner Change-91.86%
Ins Owners1.53%
Ins Owner Change0%
Market Cap30.50M
Revenue(TTM)N/A
Net Income(TTM)-58.01M
Analysts84.44
Price Target18.02 (58.35%)
Short Float %0.96%
Short Ratio0.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-59.55%
Min EPS beat(2)-139.84%
Max EPS beat(2)20.75%
EPS beat(4)2
Avg EPS beat(4)-33.67%
Min EPS beat(4)-139.84%
Max EPS beat(4)20.75%
EPS beat(8)3
Avg EPS beat(8)-27.3%
EPS beat(12)6
Avg EPS beat(12)-15.42%
EPS beat(16)8
Avg EPS beat(16)-11.11%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.95%
PT rev (3m)0.95%
EPS NQ rev (1m)35.98%
EPS NQ rev (3m)40.62%
EPS NY rev (1m)6.13%
EPS NY rev (3m)6.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.29
P/tB 1.29
EV/EBITDA N/A
EPS(TTM)-24.11
EYN/A
EPS(NY)-10.95
Fwd EYN/A
FCF(TTM)-18.25
FCFYN/A
OCF(TTM)-18.26
OCFYN/A
SpS0
BVpS8.82
TBVpS8.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -146.44%
ROE -245.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.01%
ROA(5y)-39.92%
ROE(3y)-61.74%
ROE(5y)-45.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.97
Quick Ratio 2.97
Altman-Z -18.24
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)30.09%
Cap/Depr(5y)71.16%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.55%
EPS Next Y28.11%
EPS Next 2Y24.06%
EPS Next 3Y22.78%
EPS Next 5Y13.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.5%
OCF growth 3YN/A
OCF growth 5YN/A

NEXTCURE INC / NXTC FAQ

What is the ChartMill fundamental rating of NEXTCURE INC (NXTC) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NXTC.


What is the valuation status for NXTC stock?

ChartMill assigns a valuation rating of 1 / 10 to NEXTCURE INC (NXTC). This can be considered as Overvalued.


How profitable is NEXTCURE INC (NXTC) stock?

NEXTCURE INC (NXTC) has a profitability rating of 0 / 10.


Can you provide the financial health for NXTC stock?

The financial health rating of NEXTCURE INC (NXTC) is 5 / 10.